secwatch.observer — SEC 8-K summary
======================================

Issuer:     INFINITY PHARMACEUTICALS, INC. (—)
CIK:        0001113148
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001140361-23-008332
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 2.05, 5.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Infinity Pharma to merge with MEI Pharma; Infinity stockholders to receive 1.0449 MEI shares per share
--------------------------------------------------------------------------------

- Merger consideration: each Infinity share converts into 1.0449 MEI shares; Infinity stockholders will own ~42% of combined company on fully diluted basis.
- Closing conditions include stockholder approvals, regulatory, and net cash conditions: MEI must have ≥$80M net cash if close by June 30, 2023; Infinity must have ≥$4M net cash.
- Termination fees: MEI pays Infinity $4M under certain circumstances; Infinity pays MEI $2.9M under certain circumstances.
- Post-merger leadership: David M. Urso as CEO, Robert Ilaria Jr. as CMO, Stéphane Peluso as CSO; board 8 members (4 MEI, 3 Infinity, 1 joint).
- Infinity reduces headcount by 4 positions (~13%) with ~$2M costs in Q1 2023; Lawrence Bloch terminated, Adelene Perkins appointed PFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1113148/000114036123008332/0001140361-23-008332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1113148/000114036123008332/brhc10048558_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-008332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer